Prevention and management of hyperglycemia after pancreas transplantation

Current Opinion in Organ Transplantation

Volumn 13, Issue 1, 2008, Pages 72-78

  Egidi, M Francesca ^a,b   Lin, Angello ^a   Bratton, Charles F ^a   Baliga, Prabhakar K ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

cells; Glucose intolerance; Immunosuppressants; Pancreas transplantation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BIOCHEMICAL MARKER; IMMUNOSUPPRESSIVE AGENT; INCRETIN; INSULIN; SULFONYLUREA;

ACUTE GRAFT REJECTION; APOPTOSIS; CHRONIC GRAFT REJECTION; DIABETOGENESIS; EXHAUSTION; GRAFT RECIPIENT; HUMAN; HYPERGLYCEMIA; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; METABOLISM; MOLECULE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS FUNCTION; PANCREAS ISLET; PANCREAS TRANSPLANTATION; PATHOGENESIS; PATHOLOGY; RADIOGRAPHY; REVIEW;

HUMANS; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE AGENTS; PANCREAS TRANSPLANTATION;

EID: 38149135130     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3282f44a3e     Document Type: Review

References (101)

1. Corry RJ, Shapiro R, editors. Pancreatic transplantation. New York: Informa Healthcare USA, Inc.; 2007. This recent book on pancreas transplantation gives a complete overview of the state of the art in the field and includes the most updated surgical techniques and management strategies.
2. Gerik JE. Type 2 diabetes mellitus as a heterogeneous disorder: implications for treatment. Mayo Clin Proc 2003; 78:447-456.
3. Lee SC, Pervaiz S. Apoptosis in the pathophysiology of diabetes mellitus. Int J Biochem Cell Biol 2007; 39:497-504. This excellent review provides a complete set of information on the apoptotic death circuit in the pathogenesis of diabetes. Despite the heterogenicity in etiology and clinical presentation, type I and II diabetes share at the molecular level pancreatic β-cell loss by apoptosis, which plays an important role in the development of insulin deficiency and the onset and progression of the disease.
4. Nath DS, Gruessner AC, Kandaswamy R, et al. Outcomes of pancreas transplants for patients with type 2 diabetes mellitus. Clin Transplant 2005; 19:792-797.
5. Light JA, Sasaki TM, Currier CB, et al. Successful long-term kidney-pancreas transplants regardless of C-peptide status or race. Transplantation 2001; 71:152-154.
6. Pox C, Ritzel R, Busing M, et al. Combined pancreas and kidney transplant in a lean type 2 diabetic patients: effect on insulin secretion and sensitivity. Exp Clin Endocrinol Diabetes 2002; 110:420-424.
7. Ketel B, Henry ML, Elkhammas EA, et al. Metabolic complications in combined kidney/pancreas transplantation. Transplant Proc 1992; 24:774-775.
8. Larsen LL. Pancreatic transplantation: indications and consequences. Endocr Rev 2004; 25:919-946.
9. Christiansen E, Vestergaard H, Tibell A, et al. Impaired insulin-stimulated nonoxidative glucose metabolism in pancreas-kidney transplant recipients: dose-response effects of insulin on glucose turnover. Diabetes 1996; 45:1267-1275.
10. Pfeffer F, Naucj MA, Benz S, et al. Determinants of a normal (versus impaired) oral glucose tolerance after combined pancreas-kidney transplantation in IDDM patients. Diabetologia 1996; 39:462-468.
11. Battezzati A, Benedini S, Caldara R, et al. Prediction of the long-term metabolic success of the pancreatic graft function. Transplantation 2001; 71:1560-1566.
12. Humar A, Johnson E, Gillingham KJ, et al. Venous thromboembolic complications after kidney and kidney-pancreas transplantation: a multivariate analysis. Transplantation 1998; 65:229-234.
13. Sibley RK. Pancreas transplantation. In: Sale GE, editor. The pathology of organ transplantation. Stoneham, MA: Butterworth Publishers; 1990. pp. 179-216.
14. Smith JL, Hunsinker LG, Yuh WT, et al. Appearance of type II diabetes mellitus in type I diabetic recipients of pancreas allografts. Transplantation 1989; 47:304-311.
15. Robertson PR. Consequences on β-cell function and reserve after long-term pancreas transplantation. Diabetes 2004; 53:633-644.
16. Bewick M, Mundy AR, Eaton B, et al. Endocrine function of the heterotopic pancreatic allotransplantation in dogs. III: The causes of hyperinsulinemia. Transplantation 1981; 31:23-25.
17. Luzi L, Battezzati A, Perseghin GL, et al. Lack of feedback inhibition of insulin secretion in denervated human pancreas. Diabetes 1992; 41:1632-1639.
18. Berry SM, Friend LA, McFadden DW, et al. Pancreatic denervation does not influence glucose-induced insulin response. Surgery 1994; 116:67-75.
19. Egidi MF, Stratta RJ, Trofe J, et al. Is the native pancreas more susceptible to abnormalities causing glucose intolerance than the pancreas transplant [abstract]? In: Program and Abstracts of the 7th World Congress of International Pancreas and Islet Transplant Association; 22-25 August 1999; Sydney, Australia. p. 102.
20. Gaber AO, Shokouh-Amiri H, Hathaway DK, et al. Results of pancreas transplantation with portal venous and enteric drainage. Ann Surg 1995; 221:613-624.
21. Tajra LC, Martin X, Benchaid M, et al. Long-term metabolic control in pancreas transplant patients according to three techniques. Transplant Proc 1998; 30:268-269.
22. Stratta RJ, Shokouh-Amiri H, Egidi MF, et al. Experience with portal-enteric pancreas transplantation at the University of Tennessee, Memphis. In: Corry RJ, Shapiro R, editors. Pancreatic transplantation. New York: Informa Healthcare USA, Inc.; 2007. pp. 359-390.
23. Petruzzo P, Badett L, Lefrancois N, et al. Metabolic consequences of pancreatic systemic or portal venous drainage in simultaneous pancreas-kidney transplant recipients. Diabet Med 2006; 23:654-659. The possible metabolic consequences of hyperinsulinemia secondary to pancreatic systemic drainage are analyzed and compared with PVD.
24. Dieterle CD, Arbogast H, Illner WD, et al. Metabolic follow-up after long-term pancreas survival. Eur J Endocrinol 2007; 156:603-610. This prospective study describes the long-term metabolic changes after pancreas transplantation and investigates the most reliable markers for monitoring glucose metabolism.
25. Pfeffer F, Nauck MA, Drognitz O, et al. Postoperative oral glucose tolerance and stimulated insulin secretion: a predictor of endocrine graft function more than 10 years after pancreas-kidney transplantation. Transplantation 2003; 71:1560-1565.
26. Federle MP, Hosseinzadeh K, Ferris JV, et al. Radiology aspects. In: Corry RJ, Shapiro R, editors. Pancreatic transplantation. New York: Informa Healthcare USA, Inc.; 2007. pp. 221-227.
27. Nikolaides P, Amin RK, Hwang CM, et al. Role of sonography in pancreatic transplantation. Radiographics 2003; 23:939-949.
28. Pozniak MA, Propeck PA, Kelcz F, Sollinger J. Imaging of pancreas transplants. Radiol Clin North Am 1995; 33:581-594.
29. Krebs TL, Daly B, Wong-You-Cheong J, et al. Acute pancreatic transplant rejection evaluation with dynamic contrast-enhanced MR imaging compared with histopathologic analysis. Radiology 1999; 210:437-442.
30. Papadimitriou JC, Drachenberg CB. Role of histopathology in pancreas transplantation. Curr Opin Organ Transplant 2002; 7:185-190.
31. Papadimitriou JC, Drachenberg CB, Willand A, et al. Histologic grading of acute rejection in pancreas needle biopsy: correlation to serum enzymes, glycemia, and response to immunosuppressive treatment. Transplantation 1998; 66:1741-1745.
32. Papadimitriou JC, Drachenberg CB, Klassen DK. Histologic grading of chronic pancreas allograft rejection/graft sclerosis. Am J Transplant 2003; 3:599-605.
33. Kapur S, Bonham CA, Dodson FS, et al. Strategies to expand the donor pool for pancreas transplantation. Transplantation 1999; 67:284-290.
34. Frezza EE, Corry RJ. Donor management and selection for pancreas transplantation. In: Hakim N, Stratta RJ, Gray D, editors. Pancreas and islet transplantation. New York: Oxford University Press Inc.; 2002. pp. 79-87.
35. Benedetti E, Sileri P, Grussner AC, et al. Surgical complications of pancreas transplantation. In: Hakim N, Stratta RJ, Gray D, editors. Pancreas and islet transplantation. New York: Oxford University Press Inc.; 2002. pp. 155-165.
36. Humar A, Kandaswamy R, Drangstveit B, et al. Prolonged preservation increases surgical complications after pancreas transplants. Surgery 2000; 127:545-551.
37. Sollinger HW, Odorico JS, Knechtle ST, et al. Experience with 500 simultaneous pancreas-kidney transplants. Ann Surg 1998; 228:284-296.
38. Sansalone CV, Maione G, Aseni P, et al. Surgical complications are the main cause of pancreatic allograft loss in pancreas-kidney transplant recipients. Transplant Proc 2005; 37:2651-2653.
39. Stratta RJ, Taylor RJ, Lowell JE, et al. Selective use of sandostatin in vascularized pancreas transplantation. Am J Surg 1993; 166:598-604.
40. Tamsma JT, Schaapherder AFM, van Bronswijk H, et al. Islet cell hormone release immediately after human pancreatic transplantation. Transplantation 1993; 56:1119-1123.
41. Tan M, Kandaswamy R, Sutherland DER, et al. Risks factors and impact of delayed graft function after pancreas transplants. Am J Transplant 2004; 4:758-762.
42. Troppmann C, Gruessner A, Papalois BE, et al. Delayed endocrine pancreas graft function after simultaneous pancreas-kidney transplantation. Transplantation 1996; 61:1323-1330.
43. Gaber LW, Egidi MF. Surveillance and monitoring of pancreas allografts. Curr Opin Organ Transplant 2002; 7:191-195.
44. Tesi RJ, Henry ML, Elkhammas EA, et al. The frequency of rejection episodes after combined kidney-pancreas transplant: the impact on graft survival. Transplantation 1994; 58:424-430.
45. Douzdjian V, Cooper JL, Abecassis MM, et al. Markers for pancreatic allograft rejection: comparison of serum anodal tripsinogen, serum amylase, serum creatinine and urinary amylase. Clin Transplant 1994; 8:79-82.
46. Sugitani A, Egidi MF, Gritsch HA, et al. Serum lipase as a marker for pancreatic rejection. Clin Transplant 1998; 12:175-183.
47. Brayman KL, Stephanian E, Matas AJ, et al. Analysis of infectious complications occurring after solid-organ transplantation. Arch Surg 1992; 127:38-47.
48. Hesse UJ, Sutherland DE, Simmons RL, et al. Intra-abdominal infections in pancreas transplant recipients. Ann Surg 1986; 203:153-162.
49. Berger N, Guggenbichler S, Steurer W, et al. Bloodstream infection following 217 consecutive systemic-enteric drained pancreas transplants. BMC Infect Dis 2006; 6:127.
50. Andersen SK, Gjedsted J, Christiansen C, Tonnesen E. The roles of insulin and hyperglycemia in sepsis pathogenesis. J Leukoc Biol 2004; 75:413-421.
51. Blondet JJ, Beilman GJ. Glycemic control and prevention of perioperative infection. Curr Opin Crit Care 2007; 13:421-427.
52. Tyden G, Reimholt FP, Sundkvist G, Bolinder J. Recurrence of autoimmune diabetes in recipients of cadaveric pancreatic graft. N Engl J Med 1996; 335:860-863.
53. Braghi S, Bonifacio E, Secchi A, et al. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type I diabetes. Diabetes 2000; 49:218-224.
54. Sutherland DE, Goetz FC, Sibley RK. Recurrence of disease in pancreas transplants. Diabetes 1989; 38 (Suppl 1):85-87.
55. Yoon JW, Yoon CS, Lim HW, et al. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in B-cells. Science 1999; 284:1183-1187.
56. Burke G, Ciancio G, Miller J, et al. Hyperglycemia occurring 5-8 years after simultaneous pancreas-kidney (SPK) transplantation associated with the prior development of islet cell antibodies [abstract]. Am J Transplant 2003; 3 (Suppl 5):380.
57. Sibley RK, Sutherland DER, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso-and allograft: a light and electron microscopic and immunohistochemical analysis of fours cases. Lab Inv 1985; 53:132-144.
58. Thivolet C, Abou-Amara S, Martin X, et al. Serological marker of recurrent beta cell destruction in diabetic patients undergoing pancreatic transplantation. Transplantation 2001; 69:99-103.
59. Dieterle CD, Hierl FX, Gutt B, et al. Insulin and islet autoantibodies after pancreas transplantation. Transplant Int 2005; 18:1361-1365.
60. Esmajies E, Rodriguez-Villar C, Richard MJ, et al. Recurrence of immunological markers for type 1 (insulin-dependent) diabetes mellitus in immuno-suppressed patients after pancreas transplantation. Transplantation 1998; 66:128-131.
61. Bosi E, Bottazzo GF, Secchi A, et al. Islet cell immunity in type I diabetic patients after HLA mismatched pancreas. Diabetes 1989; 38:82-84.
62. Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab 2006; 32:539-546.
63. Egidi MF. Management of hyperglycaemia after pancreas transplantation: are new immunosuppressants the answer? Drugs 2005; 65:153-166.
64. Weir MR, Fink JC. Risk of posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999; 34:1-13.
65. Wajchenbergh BL. Beta-cell failure and preservation by clinical treatment. Endocr Rev 2007; 282:187-218. New strategies for prevention of pancreatic islet exhaustion.
66. Sia C, Hainninen A. Apoptosis in autoimmune diabetes: the fate of β-cells in the cleft between life and death. Rev Diabetic Stud 2006; 3:39-46.
67. Villanueva G, Baldwin D. Rosiglitazone therapy in posttransplant diabetes mellitus. Transplantation 2005; 80:1402-1510.
68. Frias JP, Edelman SV. Incretins and their role in the management of diabetes. Curr Opin Endocrinol Diabetes Obes 2007; 14:269-276. This paper gives a comprehensive review on data from clinical trials of incretin mimetics in patients with type II diabetes.
69. Nauck MA, Busing M, Orskov C, et al. Preserved incretin effect in type 1 diabetic patients with end stage nephropathy treated by combined heterotopic pancreas after and kidney transplantation. Acta Diabetol 1993; 30:39-45.
70. Wilkinson A, Davinson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005; 19:291-298.
71. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3:178-185.
72. Arner P, Gunnarsson R, Blomdahl G, et al. Some characteristics of steroid diabetes: a study in renal transplant recipients receiving high dose corticosteroid therapy. Diabetes Care 1983; 6:23-25.
73. Gunnarsson R, Lundgren G, Magnusson G, et al. Steroid diabetes: a sign of overtreatment with steroids in the renal graft recipients? Scand J Urol Nephrol Suppl 1980; 54:135-138.
74. Hricik DE, Bartucci MR, Moir EJ, et al. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991; 51:374-377.
75. Schulak JA, Mayes JT, Moritz CE, et al. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients. Transplantation 1990; 49:327-332.
76. Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil: a prospective randomized study. Transplantation 1999; 68:1865-1874.
77. Zimmerman T, Horber F, Rodriquez N, et al. Contribution of insulin resistance to catabolic effects of prednisone on leucine metabolism in humans. Diabetes 1989; 38:1238-1244.
78. Jordan ML, Chakrabarti P, Luke P, et al. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. Transplantation 2000; 69:265-271.
79. Kaufman DB, Leventhal JR, Koffron AJ, et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 2002; 73:169-177.
80. Cantarovich D, Giral-Classe M, Hourmant M, et al. Low incidence of kidney rejection after simultaneous kidney-pancreas transplantation after antithymocyte globulin induction and in absence of corticosteroids: results of a prospective pilot study in 28 consecutive cases. Transplantation 2000; 69:1505-1508.
81. Friese CE, Sang-Mo K, Feng S, et al. Excellent short-term results with steroid-free maintenance immunosuppression in low risk simultaneous pancreas-kidney transplantation. Arch Surg 2003; 138:1121-1126.
82. Grockowiescki T, Wyzgal J, Galazka Z, et al. A retrospective study of steroid elimination in simultaneous pancreas and preemptive kidney transplant (Sppre-Ktx) recipients. Transplant Proc 2006; 11:57-59.
83. Aoun M, Eschewege P, Hamoudi Y, et al. Very early steroid withdrawal in simultaneous pancreas-kidney transplants. Nephrol Dial Transplant 2007; 22:899-905.
84. Kaufman DB, Leventhal JR, Gallon LG, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas kidney transplantation comparison with rabbit antithymocyte globulin induction: long-term results. Am J Transplant 2006; 6:331-339.
85. Gallon LG, Winot J, Chhabra D, et al. Long-term renal transplant function in recipients of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 2007; 83:1324-1329.
86. Shapiro AMJ, Lakey JRT, Ryand EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immuno-suppressive regimen. N Engl J Med 2000; 343:230-238.
87. Heisel O, Heisel R, Balshaw R, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004; 4:583-595.
88. First R, Gerber D, Hariharan S, et al. Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors and management. Transplantation 2002; 73:379-386.
89. Drachenberg CB, Klassen DK, Weir MR, et al. Islet cell damage associ\ated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68:396-402.
90. Pirsh JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63:977-983.
91. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcomes with cyclosporine versus tacrolimus. Am J Transplant 2007; 7:1506-1514. This study compares the diabetogenicity of CNIs in a large multicenter trial and the impact on patient and graft survival.
92. Malaise J, Secchi A, Caldara R, et al. Metabolic assessment after simultaneous pancreas-kidney transplantation. Transplant Proc 2005; 6:2851-2852.
93. Egidi MF, Cowan PA, Naseer A, et al. Conversion to sirolimus in solid organ transplantation: a single center experience. Transplant Proc 2003; 35:131S-137S.
94. Vincenti F, Stock P. De novo use of sirolimus immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco. Transplant Proc 2003; 35 (3 Suppl):131S-137S.
95. Havdrova T, Saudek F, Boucek P, et al. Metabolic effect of sirolimus versus mycophenolate mofetil on pancreatic graft function in the early posttransplant period. Transplant Proc 2005; 37:3544-3545.
96. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicenter study. The Rapamune US Study Group. Lancet 2000; 356:194-202.
97. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72:777-782.
98. Marcelli-Tourveille S, Hubert T, Moerman E, et al. In vivo and in vitro effect of sirolimus on insulin secretion. Transplantation 2007; 83:532-538.
99. Berg CE, Lavan BE, Rondinone CM. Rapamycin partially prevents insulin resistance induced by chronic insulin treatment. Biochem Biophys Res Commun 2002; 293:1021-1027.
100. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitors withdrawal and conversion to sirolimus. J Am Soc Nephrology 2005; 16:3128-3135.
101. Andoh TF, Lindsley J, Franceschini L, et al. Synergist effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996; 62:311-316.